- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03953443
Expression & Epigenetic Silencing of MicroRNA for Predicting Therapeutic Response and Prognosis of HPV-negative HNSCC
INST 1008: Expression and Epigenetic Silencing of MicroRNA for Predicting the Therapeutic Response and Prognosis of HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
* Part 1, Prospective Collection of Fresh Tumor-Distant Normal Pairs
The investigators will prospectively collect 25 pairs of fresh HNSCC tumor-distant normal mucosal tissue.
* Part 2, Retrospective Molecular Epidemiology Study of the Association of miRs with Therapeutic Response and Prognosis in HNSCC.
The investigators will comprehensively test the association between miR expression and miR promoter methylation, and the response to therapy and survival in all cases of surgical HPV-negative HNSCC at UNMH collected after 1990. Lip and nonkeratinizing nasopharyngeal cases will be excluded as these are etiologically distinct and related to cutaneous SCC or to EB virus infection, respectively. No cases will be excluded due to gender, age, race or ethnicity.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- University of New Mexico - Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Patients with a known or suspected diagnosis of HNSCC
- Any primary site may be included, except nonkeratinizing nasopharyngeal SCC or lip SCC.
- Patients are planned for diagnostic biopsies for suspected HNSCC, or for therapeutic surgery for HNSCC.
- Patients are naïve to radiation to the head and neck, prior to research biopsies.
- Patients have not received chemotherapy for the diagnosis of HNSCC, prior to research biopsies.
- Age > 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Patients sign an informed consent, agreeing to fresh tumor biopsy as well as distant normal mucosal biopsy for purposes of described research. Research biopsies will be in addition to planned surgery. In cases where tumor resection is planned, a representative part of the tumor will be submitted for research purposes.
Exclusion Criteria:
- Nonkeratinizing nasopharyngeal carcinoma
- Lip squamous cell carcinoma
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identify tumor specific microRNAs (miRs) whose expression increases or decreases by over 2 fold in fresh tumor vs. distant normal mucosa from patients with head and neck squamous cell carcinoma (HNSCC) negative for human papillomavirus (HPV)
Time Frame: As long as needed to collect 15 HPV-negative tumor-mucosal sample pairs and complete sequencing, up to 10 years
|
SOLiD sequencing of fresh tumor-distant normal pairs will discover miRs whose expression is altered in HNSCC tumors.
SOLiD sequencing will provide fully quantitative data for the expression of known and novel miRs.
Because HPV-related tumors comprise approximately 20% of all HNSCC and are biologically distinct from HPV negative tumors classically associated with tobacco and alcohol, only HNSCC without p16 overexpression will be used in this discovery experiment.
This restriction will increase homogeneity of the samples and the power to detect miRs associated with the etiology of HPV-negative HNSCC.
The miRs identified will be validated using qPCR assay in the tumor-normal pairs and in p16-negative HNSCC cell lines (n>15).
In addition, miRs previously reported to be dysregulated in HNSCC will be subjected to similar validation, even if not identified during the SOLiD sequencing discovery phase.
|
As long as needed to collect 15 HPV-negative tumor-mucosal sample pairs and complete sequencing, up to 10 years
|
Identify miRs whose reduced expression in HPV-negative HNSCC is due to promoter methylation
Time Frame: As long as needed to complete sequencing and analyze results, up to 5 years
|
miRs with reduced expression in tumor tissue identified under Outcome 1 will be scrutinized for CpG rich promoters by checking the UCSC database.
The methylation status of CpG rich promoters of miRs will be examined by COBRA assay in tumor vs. normal pairs (n=15) and in p16-negative HNSCC cell lines (n>15).
The heterogeneity of methylation status across the CpG rich promoter will be characterized by bisulfate sequencing using the COBRA PCR product.
The silencing of miRs by promoter methylation will be examined by comparing mean miR expression levels between the methylation categories for the tumor-normal pairs and for the HNSCC cell lines.
This is primarily a descriptive study.
|
As long as needed to complete sequencing and analyze results, up to 5 years
|
Define the statistical association between the expression of tumor specific miRs, miR methylation, and the therapeutic response and prognosis of HPV-negative HNSCC using patient medical records
Time Frame: As long as needed to collect and analyze information from medical records, up to 5 years
|
The therapeutic response and prognosis of HPV-negative HNSCC will be collected from two sources: the patient's case file from the New Mexico Tumor Registry (NMTR) and from the patient's UNMH medical record.
qRT PCR will be designed to quantify the miR expression in RNA extracted from the formalin-fixed, paraffin embedded (FFPE) tissues.
A methylation-specific PCR (MSP) will be designed to facilitate the large-scale methyl-typing in all retrospective clinical samples.
The primary analysis will be performed in HPV-negative HNSCC.
A secondary analysis will be conducted to include all HNSCC, with and without p16 overexpression.
p16 overexpression status will be adjusted in the secondary analysis.
The association between miR expression status (high or low) and miR methylation status (yes or no), and patient's PFS and OS will be examined using Kaplan-Meier survival plots and the log-rank test.
|
As long as needed to collect and analyze information from medical records, up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Garth Olson, MD, University of New Mexico Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- INST 1008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Squamous Cell Carcinoma
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Chase Heaton, MDIncyte Corporation; OncoSec Medical IncorporatedTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell CarcinomaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
Xiang LuRecruitingHead and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell CarcinomaChina
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
Washington University School of MedicineActive, not recruitingSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Yonsei UniversityCompletedHead Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell MetastaticKorea, Republic of
-
National Taiwan University HospitalUnknownHead-and-Neck Squamous Cell CarcinomaTaiwan
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
Medical College of WisconsinRecruitingResectable Head and Neck Squamous Cell CarcinomaUnited States
Clinical Trials on Not interventional
-
Weill Medical College of Cornell UniversityTerminated
-
Bagcilar Training and Research HospitalUnknown
-
University of East AngliaCompletedDementia | Hip FracturesUnited Kingdom
-
Boston Children's HospitalCompleted
-
Guy's and St Thomas' NHS Foundation TrustUnknownRespiratory Tract Infections | Healthy | Lung Infection | Droplet Spread
-
University of East AngliaCompletedDementia | Hip Fractures
-
University of British ColumbiaActive, not recruitingMyocardial Injury | Chronic Kidney Diseases | SurgeryCanada
-
University of British ColumbiaActive, not recruitingMyocardial Injury | Complication,Postoperative | Non-cardiac Surgery | High-sensitivity TroponinCanada
-
University of Texas Southwestern Medical CenterNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Recruiting
-
Technical University of MunichRecruiting